RegenxBio Inc (RGNX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

RegenxBio Inc (RegenxBio), formerly ReGenX Biosciences LLC is a provider of therapeutics for various diseases. The company develops, commercializes and licenses recombinant adeno-associated virus (AAV) gene therapy. Its products include AAV plasmids, AAV vector reporter systems and custom AAV vectors. RegenxBio employs its proprietary NAV technology platform, a gene delivery technology to develop product candidates. The company offers products for metabolic, muscle, hematologic, ocular and neurodegenerative disorders. Its products find application in the areas of gene therapy, gene modulation, protein therapeutics, genetic vaccines and protein screening. RegenxBio is headquartered in Rockville, Maryland, the US.

RegenxBio Inc (RGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
RegenxBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
RegenxBio Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
REGENXBIO Raises USD70.5 Million in Series D Financing 12
REGENXBIO Raises USD30 Million in Series C Financing 15
REGENXBIO Raises USD7.9 Million in Venture Financing 17
ReGenX Biosciences Raises US$7.9 Million In Venture Financing 18
Partnerships 19
RegenxBio Enters into Agreement with Fujifilm Diosynth Biotechnologies 19
Silverstein Foundation, RegenxBio and OrbiMed Advisors Form Joint Venture 20
ABL Enters into Contract Manufacturing Agreement with RegenxBio 21
Fidelity Biosciences Forms Joint Venture With ReGenX Biosciences 22
Licensing Agreements 23
Prevail Therapeutics Enters into Licensing Agreement with RegenxBio 23
AveXis Enters into Licensing Agreement with Regenxbio 24
RegenxBio Exercises its Option Agreement with Voyager Therapeutics 26
Biogen Enters into Licensing Agreement with RegenxBio 27
Audentes Therapeutics Enters Into Licensing Agreement With RegenxBio 28
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 29
ReGenX Biosciences Enters into Option And Licensing Agreement with Dimension Therapeutics 31
Regenxbio Enters into Licensing Agreement with University of Pennsylvania and University of Minnesota 32
Voyager Therapeutics Enters into Licensing Agreement with ReGenX Biosciences 33
ReGenx Enters Into Licensing Agreement With AAVLife 35
AveXis Amends Licensing Agreement With ReGenX Biosciences 36
ReGenX Biosciences Enters Into Licensing Agreement With Lysogene 37
ReGenX Biosciences Amends Licensing Agreement With Dimension Therapeutics 38
Audentes Therapeutics Enters Into Licensing Agreement with ReGenX Biosciences 39
Asklepios BioPharma Enters Into Licensing Agreement With REGENX Biosciences For Hemophilia A 40
ReGenX Biosciences Enters Into Licensing Agreement With Esteve 41
Equity Offering 42
RegenxBio Prices Public Offering of Shares for USD75.9 Million 42
RegenxBio Raises USD159.4 Million in IPO 44
Acquisition 46
RegenxBio to Acquire Dimension Therapeutics 46
RegenxBio Inc - Key Competitors 48
RegenxBio Inc - Key Employees 49
RegenxBio Inc - Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Recent Developments 51
Strategy And Business Planning 51
May 15, 2018: REGENXBIO Joins the Mucopolysaccharidosis Community to Advance Research and Innovation 51
Financial Announcements 52
May 08, 2018: REGENXBIO Reports First Quarter 2018 Financial Results and Recent Operational Highlights 52
Mar 06, 2018: REGENXBIO Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights 54
Nov 08, 2017: REGENXBIO Reports Third Quarter 2017 Financial Results and Recent Operational Highlights 56
Aug 08, 2017: REGENXBIO Reports Second Quarter 2017 Financial Results and Recent Operational Highlights 58
May 09, 2017: REGENXBIO Reports First Quarter 2017 Financial Results and Recent Operational Highlights 60
Mar 07, 2017: REGENXBIO Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Operational Highlights 62
Jan 06, 2017: REGENXBIO Provides Year-End 2016 Corporate Update 64
Corporate Communications 66
May 29, 2018: REGENXBIO Names Alexandra Glucksmann As Board Director 66
Mar 28, 2017: REGENXBIO Enhances and Expands Scientific Leadership 67
Clinical Trials 68
Feb 08, 2018: REGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD 68
Sep 20, 2017: REGENXBIO Announces Completion of Dosing of First Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD 69
Aug 11, 2017: REGENXBIO to Present on RGX-314 Gene Therapy Program for Wet AMD at 35th Annual Scientific Meeting of the American Society of Retina Specialists 70
Other Significant Developments 71
Jan 04, 2018: REGENXBIO Provides Year-End 2017 Corporate Update 71
Appendix 74
Methodology 74
About GlobalData 74
Contact Us 74
Disclaimer 74

List Of Tables

List of Tables
RegenxBio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
RegenxBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
RegenxBio Inc, Deals By Therapy Area, 2012 to YTD 2018 9
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
REGENXBIO Raises USD70.5 Million in Series D Financing 12
REGENXBIO Raises USD30 Million in Series C Financing 15
REGENXBIO Raises USD7.9 Million in Venture Financing 17
ReGenX Biosciences Raises US$7.9 Million In Venture Financing 18
RegenxBio Enters into Agreement with Fujifilm Diosynth Biotechnologies 19
Silverstein Foundation, RegenxBio and OrbiMed Advisors Form Joint Venture 20
ABL Enters into Contract Manufacturing Agreement with RegenxBio 21
Fidelity Biosciences Forms Joint Venture With ReGenX Biosciences 22
Prevail Therapeutics Enters into Licensing Agreement with RegenxBio 23
AveXis Enters into Licensing Agreement with Regenxbio 24
RegenxBio Exercises its Option Agreement with Voyager Therapeutics 26
Biogen Enters into Licensing Agreement with RegenxBio 27
Audentes Therapeutics Enters Into Licensing Agreement With RegenxBio 28
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 29
ReGenX Biosciences Enters into Option And Licensing Agreement with Dimension Therapeutics 31
Regenxbio Enters into Licensing Agreement with University of Pennsylvania and University of Minnesota 32
Voyager Therapeutics Enters into Licensing Agreement with ReGenX Biosciences 33
ReGenx Enters Into Licensing Agreement With AAVLife 35
AveXis Amends Licensing Agreement With ReGenX Biosciences 36
ReGenX Biosciences Enters Into Licensing Agreement With Lysogene 37
ReGenX Biosciences Amends Licensing Agreement With Dimension Therapeutics 38
Audentes Therapeutics Enters Into Licensing Agreement with ReGenX Biosciences 39
Asklepios BioPharma Enters Into Licensing Agreement With REGENX Biosciences For Hemophilia A 40
ReGenX Biosciences Enters Into Licensing Agreement With Esteve 41
RegenxBio Prices Public Offering of Shares for USD75.9 Million 42
RegenxBio Raises USD159.4 Million in IPO 44
RegenxBio to Acquire Dimension Therapeutics 46
RegenxBio Inc, Key Competitors 48
RegenxBio Inc, Key Employees 49
RegenxBio Inc, Subsidiaries 50

List Of Figures

List of Figures
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

RegenxBio Inc (RGNX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

RegenxBio Inc (RegenxBio), formerly ReGenX Biosciences LLC is a provider of therapeutics for various diseases. The company develops, commercializes and licenses recombinant adeno-associated virus (AAV) gene therapy. Its products include

USD 250 View Report

REGENXBIO Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

REGENXBIO Inc Company Profile is a detailed strategic and analytical report on REGENXBIO Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

REGENXBIO Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

REGENXBIO Inc Company Profile is a detailed strategic and analytical report on REGENXBIO Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review

RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

USD 125 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available